A recent editorial surveys cannabis legalization trends across more than a dozen countries, reporting that use prevalence has risen in jurisdictions that legalized and that some adverse health outcomes, including pediatric poisonings and emergency visits, appear to have increased. While these observations merit clinical attention, the editorial does not systematically appraise the evidence it cites, meaning its causal claims should be treated as hypotheses rather than established conclusions.

Cannabis legalization is accelerating worldwide, and clinicians are increasingly confronted with questions about safety that outpace the available evidence. As over fifty countries now permit some form of medical cannabis use, and recreational markets expand in North America and beyond, the gap between regulatory ambition and clinical data grows wider. Pediatric accidental ingestions, emergency department burden, and rising prevalence of cannabis use disorder all demand informed clinical awareness. Understanding what the current policy landscape actually tells us, and what it does not, is essential for responsible patient counseling.

Cannabis legalization has moved rapidly from a policy outlier to a global phenomenon. Over fifty countries now permit regulated medical cannabis use, and recreational markets have opened in Canada, multiple U.S. states, and Australia’s Capital Territory, among others. As these legal frameworks have expanded, so has population-level cannabis use. The 2019 World Drug Report estimated that 188 million people aged 15 to 64, or roughly 3.8 percent of that population, used cannabis globally. Against this backdrop, Ahmad and Haque offer a narrative editorial drawing on national surveys, systematic reviews, and epidemiological data from across Asia-Pacific and North America to argue that legalization has brought measurable increases in both use and harm, and that current regulation is insufficient to manage the public health consequences.

Among the specific data points cited, a Canadian meta-analysis reported annual cannabis use prevalence rising from approximately 9 percent before legalization (1985 to 2017) to 25 percent afterward (2018 to 2021). A systematic review cited a relative risk of 4.31 (95% CI 2.30 to 8.07) for pediatric emergency department visits post-legalization. The editorial also highlights links between higher-potency products now available in legal markets and increased rates of cannabis use disorder, psychosis, and treatment-seeking. However, the editorial does not employ a systematic search strategy or formal quality appraisal of its cited sources, which substantially limits the strength of its causal inferences. The authors themselves call for comprehensive regulatory measures including potency caps, advertising bans, and standardized testing, drawing an explicit analogy to the opioid crisis. The evidence the editorial assembles is directionally concerning but methodologically insufficient to establish that legalization itself caused the observed harms.

The safety concerns raised in this editorial are real, and any clinician working in cannabis medicine encounters them regularly. Pediatric exposures, high-potency concentrates reaching patients who may not be prepared for them, the growing prevalence of cannabis use disorder: these are not theoretical worries. Where the editorial falls short is in the leap from correlation to causation. Legalization coincides with many other changes, from product innovation to shifting social norms to improved detection and reporting. Framing legalization itself as the primary driver oversimplifies a landscape that requires more careful analysis, and comparing cannabis to the opioid crisis, while attention-grabbing, risks distorting the actual magnitude of harm.

In my practice, I see both the promise and the pitfalls of expanded access. I counsel patients on dosing, product selection, and harm avoidance with the same rigor I would bring to any therapeutic decision. What I find most useful about this kind of editorial is not its specific statistics, which warrant scrutiny, but its reminder that access without education and regulation is not sufficient. I consistently advocate for mandatory childproof packaging, clear labeling, and patient education as non-negotiable elements of responsible cannabis care.

This editorial sits early in the research arc, functioning as a policy-oriented synthesis rather than a source of new evidence. It is most useful as a quick reference to the geographic breadth of legalization and a catalog of commonly cited safety concerns. Clinicians should recognize that the specific prevalence and risk statistics quoted depend heavily on the underlying studies, which the editorial does not critically evaluate. The Canadian meta-analysis showing a leap from 9 to 25 percent annual prevalence, for example, requires context: changes in survey methodology, social desirability bias, and the shift from illicit to legal purchasing all complicate interpretation. Similarly, the relative risk figure for pediatric emergency visits, while alarming, derives from a systematic review whose inclusion criteria and heterogeneity are not discussed in the editorial itself.

From a pharmacological standpoint, the editorial’s concern about rising product potency is well-placed. THC concentrations in commercially available concentrates can exceed 80 percent, and there is growing evidence that higher-potency products are associated with greater risk of dependence and acute psychiatric symptoms. Clinicians prescribing or guiding cannabis use should be aware that the regulatory environment varies dramatically by jurisdiction, and that patients may access products far more potent than those studied in most clinical trials. One concrete step practitioners can take today is to proactively discuss product potency and route of administration at every cannabis-related visit, particularly with patients new to legal markets or those with psychiatric vulnerability.

Have thoughts on this? Share it: